BioSpace reviewed the third-quarter 2020 financial announcements from some of the biopharma industry’s leading players.
Shares of CStone Pharmaceuticals were up after Pfizer invested $200 million into the company for a nearly 10% stake to support the development of a checkpoint inhibitor aimed at the oncology market in China.
Sanofi announced the acquisition of Principia Biopharma in a deal valued at about $3.68 billion as the French company continues to transform its R&D division to more heavily emphasize oncology and other lucrative programs.
San Diego-based Ligand Pharmaceuticals is acquiring San Diego-based Pfenex for a total deal transaction of up to $516 million.
A new $1 billion fund backed by 20 drugmakers including Merck & Co. Inc. and Pfizer Inc. is aiming to bolster struggling antibiotic companies and sustain a pipeline for new treatments.
New information released by GlobalData showed that there are now more than 718 pipeline drugs associated with COVID-19.
Bristol-Myers Squibb is taking aim at harnessing CRISPR-based solutions to treat certain cancers with a $65 million collaboration with Montreal-based Repare Therapeutics.
Neurotrope and Metuchen Pharmaceuticals announced the companies have merged in an all-stock deal to form Petros Pharmaceuticals, which is focused on men’s health conditions.
As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.
MedAdNews spoke to Bill Dreitlein, Senior Director, Pipeline & Drug Surveillance at OptumRx, about the state of the industry’s prescription drug pipeline and what enticing prospects will soon emerge.